Accessibility Menu
GenSight Biologics logo

GenSight Biologics(OTC) GSGTF

Market Cap$21.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-99%
5 Year-99%
1 Year-63%
1 Month+0%
$0.09
+0.00%
+0.00Today
GenSight Biologics last closing stock price
MetricPriceDate
Last closeUSD 0.092026-08-14
GenSight Biologics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.092026-06-17
1 month+0%USD 0.092026-06-17
3 month-52.66%USD 0.192025-11-03
Year to date-52.66%USD 0.192025-11-03
1 year-62.5%USD 0.242025-03-25
3 year-88.08%USD 0.762023-08-04
5 year-98.98%USD 8.852021-08-09
Since inception-98.74%USD 7.132018-01-22

GenSight Biologics Financials at a Glance

Market Cap

$21.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.50M

Net Income (TTM)

-€26.04M

EPS (TTM)

-$0.09

P/E Ratio

-0.99

Dividend

$0.00

Beta (Volatility)

-123.88 (Low)

Price

$0.09

Volume

300

Open

$0.09

Previous Close

$0.09

Daily Range

$0.09 - $0.09

52-Week Range

$0.09 - $0.19

Estimated Earnings Date

Sep 29, 2026

GSGTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on developing innovative treatments for serious eye and central nervous system disorders. The company specializes in gene therapy approaches targeting mitochondrial dysfunction and neurodegeneration.

Products and Services
  • Primary drug candidate LUMEVOQ (GS010) for Leber hereditary optic neuropathy
  • GS030 in Phase I/II trials for retinitis pigmentosa
  • Preclinical programs targeting various ophthalmic and neurodegenerative conditions
Growth Outlook
  • Ongoing Phase III trials for LUMEVOQ may lead to market approval
  • Expansion of pipeline with GS030 and other preclinical candidates
  • Potential partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly revenue of -€47,000 indicates ongoing challenges
  • Trailing twelve months (TTM) net income of -€14.26 million reflects significant investment in R&D
  • Cash and cash equivalents of €2.41 million as of last quarter
GenSight Biologics S.A. operates in a highly specialized sector, focusing on groundbreaking therapies that address unmet medical needs. The company's commitment to advancing its therapeutic pipeline is evident through its ongoing clinical trials and research initiatives. Despite facing financial challenges, the potential for future growth remains strong, particularly with the advancement of its lead candidates and the exploration of strategic partnerships. Investors may find interest in the company's innovative approach to treating debilitating conditions, as well as its focus on leveraging cutting-edge gene therapy technologies.
AI Generated • Jul 28, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Laurence Rodriguez

Website

www.gensight-biologics.com

Headquarters

Paris, IF 75012, FR

GSGTF Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1168400.00%

Net Income Margin

-1203600.00%

Return on Equity

42.20%

Return on Capital

N/A

Return on Assets

-145.78%

Earnings Yield

-1.01%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$21.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

234.47M

Volume

300

Avg. Volume

11.127

Financials (TTM)

Gross Profit

€1.50M

Operating Income

-€29.02M

EBITDA

-€21.76M

Operating Cash Flow

-€22.58M

Capital Expenditure

€6.49M

Free Cash Flow

-€23.97M

Cash & ST Invst.

€2.41M

Total Debt

€12.86M

GenSight Biologics Performance Analysis

GenSight Biologics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 2,713,616-56.5%
20232023-12-31EUR 1,369,773-49.5%
20242024-12-31EUR 1,622,53618.5%
20252025-12-31EUR 1,129-99.9%
GenSight Biologics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30710.6%
Q42024-12-31-113.2%
Q22025-06-30121.1%
Q42025-12-31-197.9%
GenSight Biologics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.63-16.4%
20232023-12-31EUR -0.59-6.4%
20242024-12-31EUR -0.16-73.0%
20252025-12-31EUR -0.09-42.1%
GenSight Biologics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3074.8%
Q42024-12-31-40.8%
Q22025-06-3045.4%
Q42025-12-3150.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

-€47.00K

+83.4%

Gross Profit

-€47.00K

+98.0%

Gross Margin

100.00%

N/A

Market Cap

$21.10MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.62M

N/A

Employees

13

N/A

Net Income

-€5.07M

+64.5%

EBITDA

-€4.53M

+60.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€2.41M

+13.1%

Total Debt

€12.86M

-30.2%

Accounts Receivable

€1.58M

+157540.9%

Inventory

€0.00

N/A

Long Term Debt

€9.22M

+49.8%

Short Term Debt

€3.64M

-79.0%

Return on Assets

-1.46%

N/A

Return on Invested Capital

2.65%

N/A

Free Cash Flow

-€7.88M

+7.0%

Operating Cash Flow

-€6.49M

+23.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOVNFBioInvent International AB (publ)
$3.29+0.00%
VBIZFViva Biotech Holdings
$0.17+0.00%
SOLTFNxera Pharma Co., Ltd.
$5.01+0.00%
AGYTFAllergy Therapeutics plc
$0.15+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About GSGTF

What is the current price of GenSight Biologics?

GenSight Biologics is trading at $0.09 per share.

What is the 52-week range for GenSight Biologics?

Over the past 52 weeks, GenSight Biologics has traded between $0.09 and $0.19.

How much debt does GenSight Biologics have?

As of the most recent reporting period, GenSight Biologics reported total debt of €15.11M.

How much cash does GenSight Biologics have on hand?

GenSight Biologics reported €2.84M in cash and cash equivalents in its most recent financial results.

What is GenSight Biologics’s dividend yield?

GenSight Biologics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services